ライフサイエンスコーパス: treprostinil

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 [31%] sildenafil, and 233 [36%] subcutaneous treprostinil).

2 No serious adverse events were attributed to treprostinil.

3 sence of atrial natriuretic peptide, NO, and treprostinil.

4 ipient mice were subcutaneously administered treprostinil (0.15 mg kg(-1) 8 h(-1)) for 10 days.

5 ents withdrew from the study prematurely (13 treprostinil, 10 placebo).

6 osentan received either 30 microg of inhaled treprostinil 4 times daily (n = 6) or 45 microg 4 times

7 The addition of inhaled treprostinil, a long-acting prostacyclin analog, might b

8 We tested the hypothesis that treprostinil, a prostacyclin analog approved for the tre

9 Treprostinil, a stable prostacyclin analogue with a half

10 human HSPCs, which had been pretreated with treprostinil and forskolin, enhanced survival of lethall

11 amic differences associated with intravenous treprostinil are clinically important requires longer fo

12 evaluated the safety and efficacy of inhaled treprostinil as add-on therapy to oral bosentan in patie

13 Borg score were maintained with intravenous treprostinil at Week 12 versus intravenous epoprostenol

14 rt that PGI(2) analogs (iloprost, cicaprost, treprostinil) differentially modulate the response of mu

15 The intravenous treprostinil dose was adjusted to minimize symptoms/side

16 In addition, iloprost and treprostinil enhanced BMP-induced phosphorylation of Sma

17 al of recipient mice was causally related to treprostinil-enhanced CXCR4-dependent migration of HSPCs

18 50 augmented atrial natriuretic peptide- and treprostinil-evoked pulmonary vascular relaxation in iso

19 mptomatic on bosentan or sildenafil, inhaled treprostinil improves exercise capacity and quality of l

20 assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) pa

21 epoprostenol, chronic subcutaneously infused treprostinil, inhaled iloprost, and oral beraprost.

22 Treprostinil inhibited phagocytosis, bacterial killing,

23 educed BMPR-II expression, we confirmed that treprostinil inhibited smooth muscle cell proliferation

24 valence between subcutaneous and intravenous treprostinil, intravenous treprostinil may have an overa

25 The prostacyclin analog treprostinil is also efficacious by subcutaneous infusio

26 from intravenous epoprostenol to intravenous treprostinil is safe and effective; whether the hemodyna

27 This trial suggests that inhaled treprostinil is safe, well tolerated, and associated wit

28 us and intravenous treprostinil, intravenous treprostinil may have an overall better risk-benefit pro

29 effects of iloprost, carbaprostacyclin, and treprostinil on the regulation of phagocytosis, bacteria

30 from intravenous epoprostenol to intravenous treprostinil over 24 to 48 h.

31 the trough period, just before inhalation of treprostinil (p = 0.009).

32 Treprostinil, proposed to dilate by activating TASK-1, w

33 nto the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Ar

34 Treprostinil stimulates the engraftment of human and mur

35 ant intravenous epoprostenol or subcutaneous treprostinil therapy.

36 in part to the previously unknown ability of treprostinil to stimulate the EP2 receptor.

37 Treprostinil (TRE), a prostacyclin analogue with extende

38 0%) or sildenafil were randomized to inhaled treprostinil (up to 54 mug) or inhaled placebo 4 times d

39 Inhaled treprostinil was associated with an increase in 6MWD at

40 onists tested in combination with forskolin, treprostinil was most efficacious in raising intracellul

41 In the remaining 11 patients, inhaled treprostinil was safe and well tolerated.

42 Inhaled treprostinil was safe and well-tolerated.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。